Congress has taken a historic step forward in the fight against cancer. Thanks to the leadership of its bipartisan sponsors, and the work of advocates across the country, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act is now law following the President’s signature. Medicare will have an MCED benefit category, and along […]
A Historic Moment in the Fight Against Cancer Read More »
The potential life-saving impact of reducing Stage IV disease and detecting more cancers at Stage III When people think about cancer screening, the emphasis is almost always on finding cancers as early as possible. That goal makes intuitive sense, but it can lead to an important oversight. The greatest threat to improving patient outcomes is
Why Finding Cancers Before It’s Too Late Matters More Than Ever Read More »
As the multi-cancer early detection (MCED) field evolves, we and others have asserted that it is essential – in order for individuals to have confidence in a test – that it must have demonstrated performance in a prospective trial in the intended use population (Ofman 2025). In addition, payor and large health system adoption of
Cancer screening has transformed outcomes for several cancers, but the vast majority of cancer deaths still occur in patients who have cancers without recommended screening tests. Multi-cancer early detection (MCED) tests can help address that gap. Rather than screening for one cancer at a time, the Galleri® MCED test looks for a shared cancer signal
By Joshua Ofman MD, MSHS, GRAIL President; Megan P. Hall Ph.D., GRAIL Medical Affairs; Christina Clarke Dur Ph.D. GRAIL Cancer Epidemiology Multi-cancer early detection (MCED) tests hold enormous promise, but will only achieve their public health and clinical impact if the tests are validated rigorously in the appropriate “intended use” population: adults at elevated risk
We believe screening individuals for many types of cancer with a multi-cancer early detection (MCED) test represents a significant opportunity to reduce the burden of cancer. Today, with a unanimous vote to advance the “Nancy Gardner Sewell Medicare Multi-Detection Early Detection Screening Coverage Act,” the House Committee on Ways and Means took an important step
GRAIL applauds policymakers’ commitment to MCED access Read More »
We believe screening individuals for many types of cancer with a multi-cancer early detection (MCED) test represents a significant opportunity to reduce the burden of cancer. However, without Congressional action, Medicare beneficiaries and their doctors may face significant delays in accessing these innovative screening tests once they are FDA-approved. Led by the American Cancer Society’s
GRAIL stands with policymakers and stakeholders for Medicare access framework Read More »
View the presentation deck here.
GRAIL Sponsored Industry Theater at ASCO 2024 Read More »
The NHS-Galleri trial, which started enrolling participants in 2021, was designed to inform implementation of the Galleri test as a national screening programme if recommended by the UK National Screening Committee on the basis of the final study results, which are expected in 2026. The trial was designed with three consecutive years of screening in
